Gastrointestinal Cancer News

This year’s American Association for Cancer Research Annual Meeting — titled “Research Propelling Cancer Prevention and Cures” — featured many studies that showed dramatic improvements and promising new therapies across cancers, conducted by the nation’s leading researchers and clinicians.

Hepatitis C virus infection was associated with an increased risk for cancers other than hepatocellular carcinoma among elderly patients, a registry-based case–control study found.

Patients with cancer who are educated about the benefits of palliative care are more likely to consider incorporating it into their treatment, according to results of a study by the American Psychological Association.

A patient feeling in control of scheduling and planning a colorectal screening exam were some of the most important factors in determining if they underwent the procedure, according to research recently published in the American Journal of Preventive Medicine.

William S. Small, Jr., MD, FACRO, FACR, FASTRO, chair of the department of radiation oncology at Loyola University Health System, has been named to the health system’s board of directors.

Higher dietary intake of rice bran and navy beans resulted in changes to the gut microbiome and reduced colorectal cancer cell growth in colorectal cancer survivors, according to the results of a randomized controlled trial presented at the American Association for Cancer Research Annual Meeting.

Microarray-trained models, which include molecular data, better predicted the recurrence of colorectal cancer than models that used clinical data, according to study findings presented at the Society of Surgical Oncology’s Annual Cancer Symposium.

CMS included Cologuard, an FDA-approved, non-invasive colon cancer screening test created by Exact Sciences Corp., in its 2017 Medicare Advantage Star Ratings program, according to a recent press release.

A phase 2 trial designed to evaluate demcizumab in combination with paclitaxel plus gemcitabine in treatment-naive patients with metastatic pancreatic cancer failed to meet its primary endpoint of PFS, according to the drug’s manufacturer.

A 74-year-old man with newly diagnosed, biopsy-proven esophageal squamous cell carcinoma of the mid-esophagus underwent initial staging with fluorodeoxyglucose PET/CT examination as part of routine clinical care.